Triglyceride and Glucose Index as a Screening Tool for Nonalcoholic Liver Disease in Patients with Metabolic Syndrome

被引:14
作者
Amzolini, Anca Maria [1 ,2 ]
Fortofoiu, Mircea-Catalin [1 ,2 ]
Alhija, Anca Barau [1 ,2 ]
Vladu, Ionela Mihaela [3 ]
Clenciu, Diana [3 ]
Mitrea, Adina [3 ]
Fortofoiu, Maria [2 ,4 ]
Matei, Daniela [5 ]
Diaconu, Magdalena [6 ]
Tudor, Marinela Sinziana [7 ]
Micu, Elena Simona [1 ,2 ]
机构
[1] Univ Med & Pharm Craiova, Fac Med, Dept Med Semiol, Craiova 200349, Romania
[2] Philanthropy Clin Municipal Hosp Craiova, Dept Internal Med 2, Craiova 200143, Romania
[3] Univ Med & Pharm Craiova, Dept Diabet Nutr & Metab Dis, Craiova 200349, Romania
[4] Univ Med & Pharm Craiova, Dept Emergency Med, Craiova 200349, Romania
[5] Univ Med & Pharm Craiova, Dept Physiotherapy, Craiova 200349, Romania
[6] Univ Med & Pharm Craiova, Dept Pharmacol, Craiova 200349, Romania
[7] Univ Med & Pharm Craiova, Doctoral Sch, Craiova 200349, Romania
关键词
nonalcoholic liver disease; triglyceride and glucose index; metabolic syndrome; liver biopsy; obesity; INSULIN-RESISTANCE; CARDIOVASCULAR EVENTS; CHRONIC HEPATITIS; PRODUCT; IMPACT;
D O I
10.3390/jcm11113043
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Nonalcoholic fatty liver disease (NAFLD) is regarded as a component of metabolic syndrome, which involves insulin resistance (IR) as the primary physiopathological event. The aim of this study was to establish the association between IR, assessed using the triglyceride and glucose index (TyG), and histopathological features of NAFLD lesions. Methods: The study included 113 patients with metabolic syndrome. Fasting plasma glucose (FPG), fasting lipid profiles and liver enzymes were measured. IR was assessed by the TyG index. Liver biopsy was performed for assessment steatosis and fibrosis. Results: the TyG index had a mean value of 8.93 +/- 1.45, with a higher value in the patients with overweight (p = 0.002) and obesity (p = 0.004) characteristics than in the patients with normal weight. The TyG index mean value was 8.78 +/- 0.65 in subjects without NASH, 8.91 +/- 0.57 in patients with borderline NASH and 9.13 +/- 0.55 in patients with definite NASH. A significant difference was found between subjects without NASH and the ones with definite NASH (p = 0.004), as well as in patients with early fibrosis vs. those with significant fibrosis. The analysis of the area under the ROC curve proved that the TyG index is a predictor of NASH (p = 0.043). Conclusion: the TyG index is a facile tool that can be used to identify individuals at risk for NAFLD.
引用
收藏
页数:11
相关论文
共 29 条
[1]   Reduced incidence of type 2 diabetes in patients with chronic hepatitis C virus infection cleared by direct-acting antiviral therapy: A prospective study [J].
Adinolfi, Luigi E. ;
Petta, Salvatore ;
Fracanzani, Anna L. ;
Nevola, Riccardo ;
Coppola, Carmine ;
Narciso, Vincenzo ;
Rinaldi, Luca ;
Calvaruso, Vincenza ;
Pafundi, Pia Clara ;
Lombardi, Rosa ;
Staiano, Laura ;
Di Marco, Vito ;
Solano, Antonio ;
Marrone, Aldo ;
Saturnino, Mariarosaria ;
Rini, Francesca ;
Guerrera, Barbara ;
Troina, Graziano ;
Giordano, Mauro ;
Craxi, Antonio ;
Sasso, Ferdinando C. .
DIABETES OBESITY & METABOLISM, 2020, 22 (12) :2408-2416
[2]   Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: A prospective multicentre study [J].
Adinolfi, Luigi Elio ;
Petta, Salvatore ;
Fracanzani, Anna Ludovica ;
Coppola, Carmine ;
Narciso, Vincenzo ;
Nevola, Riccardo ;
Rinaldi, Luca ;
Calvaruso, Vincenza ;
Staiano, Laura ;
Di Marco, Vito ;
Marrone, Aldo ;
Pafundi, Pia Clara ;
Solano, Antonio ;
Lombardi, Rosa ;
Sasso, Ferdinando Carlo ;
Saturnino, Mariarosaria ;
Rini, Francesca ;
Guerrera, Barbara ;
Troina, Graziano ;
Giordano, Mauro ;
Craxi, Antonio .
ATHEROSCLEROSIS, 2020, 296 :40-47
[3]   Non-alcoholic fatty liver disease [J].
Alba, LM ;
Lindor, K .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 17 (08) :977-986
[4]   Harmonizing the Metabolic Syndrome A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity [J].
Alberti, K. G. M. M. ;
Eckel, Robert H. ;
Grundy, Scott M. ;
Zimmet, Paul Z. ;
Cleeman, James I. ;
Donato, Karen A. ;
Fruchart, Jean-Charles ;
James, W. Philip T. ;
Loria, Catherine M. ;
Smith, Sidney C., Jr. .
CIRCULATION, 2009, 120 (16) :1640-1645
[5]   Nonalcoholic Fatty Liver Disease (NAFLD) Activity Score and the Histopathologic Diagnosis in NAFLD: Distinct Clinicopathologic Meanings [J].
Brunt, Elizabeth M. ;
Kleiner, David E. ;
Wilson, Laura A. ;
Belt, Patricia ;
Neuschwander-Tetri, Brent A. .
HEPATOLOGY, 2011, 53 (03) :810-820
[6]   Insulin resistance: A metabolic pathway to chronic liver disease [J].
Bugianesi, E ;
McCullough, AJ ;
Marchesini, G .
HEPATOLOGY, 2005, 42 (05) :987-1000
[7]   Non-alcoholic fatty liver disease: The mist gradually clears [J].
de Alwis, Nimantha Mark Wilfred ;
Day, Christopher Paul .
JOURNAL OF HEPATOLOGY, 2008, 48 :S104-S112
[8]   Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis [J].
Dowman, J. K. ;
Tomlinson, J. W. ;
Newsome, P. N. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 33 (05) :525-540
[9]   Long-term follow-up of patients with NAFLD and elevated liver enzymes [J].
Ekstedt, Mattias ;
Franzen, Lennart E. ;
Mathiesen, Ulrik L. ;
Thorelius, Lars ;
Holmqvist, Marika ;
Bodemar, Goran ;
Kechagias, Stergios .
HEPATOLOGY, 2006, 44 (04) :865-873
[10]   Nonalcoholic fatty liver disease [J].
Erickson, Sandra K. .
JOURNAL OF LIPID RESEARCH, 2009, 50 :S412-S416